Determinants of cerebrospinal fluid arsenic concentration in patients with acute promyelocytic leukemia on oral arsenic trioxide therapy

Blood

Volumn 112, Issue 9, 2008, Pages 3587-3590

  Au, Wing Yan ^a   Tam, Sidney ^a   Fong, Bonnie M ^a   Kwong, Yok Lam ^a  

^a QUEEN MARY HOSPITAL   (Hong Kong)

Author keywords

[No Author keywords available]

Indexed keywords

ARSENIC TRIOXIDE; CYTARABINE; IDARUBICIN; METHOTREXATE; RETINOIC ACID; ANTINEOPLASTIC AGENT; ARSENIC; ORGANOARSENIC DERIVATIVE; OXIDE;

ABSENCE OF SIDE EFFECTS; ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER PATIENT; CHEMOPROPHYLAXIS; CLINICAL ARTICLE; DRUG BLOOD LEVEL; DRUG CEREBROSPINAL FLUID LEVEL; DRUG PENETRATION; FEMALE; HUMAN; LEUKEMIA RELAPSE; MALE; PRIORITY JOURNAL; PROMYELOCYTIC LEUKEMIA; BLOOD; CEREBROSPINAL FLUID; INTRASPINAL DRUG ADMINISTRATION; MIDDLE AGED; ORAL DRUG ADMINISTRATION; RECURRENT DISEASE;

ADMINISTRATION, ORAL; ADULT; AGED; ANTINEOPLASTIC AGENTS; ARSENIC; ARSENICALS; CYTARABINE; FEMALE; HUMANS; INJECTIONS, SPINAL; LEUKEMIA, PROMYELOCYTIC, ACUTE; MALE; METHOTREXATE; MIDDLE AGED; OXIDES; RECURRENCE;

EID: 55749109523     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2008-06-161000     Document Type: Article

References (15)

1. Specchia G, Lo Coco F, Vignetti M, et al. Extramedullary involvement at relapse in acute promyelocytic leukemia patients treated or not with all-trans retinoic acid: a report by the Gruppo Italiano Malattie Ematologiche dell'Adulto. J Clin Oncol. 2001;19:4023-4028.
2. de Botton S, Sanz MA, Chevret S, et al. Extramedullary relapse in acute promyelocytic leukemia treated with all-trans retinoic acid and chemotherapy. Leukemia. 2006;20:35-41.
3. Tallman MS. Treatment of relapsed or refractory acute promyelocytic leukemia. Best Pract Res Clin Haematol. 2007;20:57-65.
4. Au WY, Tam S, Fong BM, Kwong YL. Elemental arsenic entered the cerebrospinal fluid during oral arsenic trioxide treatment of meningeal relapse of acute promyelocytic leukemia. Blood. 2006;107: 3012-3013.
5. Knipp S, Gattermann N, Schapira M, Käferstein H, Germing U. Arsenic in the cerebrospinal fluid of a patient receiving arsenic trioxide for relapsed acute promyelocytic leukemia with CNS involvement. Leuk Res. 2007;31:1585-1587.
6. Au WY, Kumana CR, Kou M, et al. Oral arsenic trioxide in the treatment of relapsed acute promyelocytic leukemia. Blood. 2003;102:407-408.
7. Kwong YL, Au WY, Chim CS, Pang A, Suen C, Liang R. Arsenic trioxide- and idarubicin-induced remissions in relapsed acute promyelocytic leukaemia: clinicopathological and molecular features of a pilot study. Am J Hematol. 2001;66:274-279.
8. Au WY, Cheung GT, Yuen TW, Kumana CR, Kwong YL. Successful treatment of relapsed acute promyelocytic leukemia in a patient receiving continuous ambulatory peritoneal dialysis with oral arsenic trioxide. Arch Intern Med. 2005;165: 1067-1068.
9. Kumana CR, Au WY, Lee NS, et al. Systemic availability of arsenic from oral arsenic-trioxide used to treat patients with hematological malignancies. Eur J Clin Pharmacol. 2002;58:521-526.
10. 3 exerts dose-dependent dual effects on APL cells. Blood. 1997; 89:3345-3353.
11. Siu CW, Au WY, Yung C, et al. Effects of oral arsenic trioxide therapy on QT intervals in patients with acute promyelocytic leukemia: implications for long-term cardiac safety. Blood. 2006;108: 103-106.
12. Ade's L, Sanz MA, Chevret S, et al. Treatment of newly diagnosed acute promyelocytic leukemia (APL): a comparison of French-Belgian-Swiss and PETHEMA results. Blood. 2008;111:1078-1084.
13. Au WY, Kwong YL. Arsenic trioxide: safety issues and their management. Acta Pharmacol Sin. 2008;29:296-304.
14. Leung J, Pang A, Yuen WH, Kwong YL, Tse EW. Relationship of expression of aquaglyceroporin 9 with arsenic uptake and sensitivity in leukemia cells. Blood. 2007;109:740-746.
15. Wang L, Zhou GB, Liu P, et al. Dissection of mechanisms of Chinese medicinal formula Realgar-Indigo naturalis as an effective treatment for promyelocytic leukemia. Proc Natl Acad Sci U S A. 2008;105:4826-4831.